Advancing immunotherapies targeting “dark genome” antigens, specifically HERV-K. Aberrant activation and expression of HERV-K in chronic inflammation, metabolic stress, cancer, and aging — drive immune evasion, senescence, and metabolic dysfunction and disease. By breaking immune tolerance to HERV-K, HERVolution is developing differentiated, off-the-shelf therapies that sit at the intersection of inflammation, type-2 diabetes disease, oncology, and longevity. 

HERVolution Therapeutics

J. Robert Coleman

This department focuses on managing and guiding investments to optimize returns and support strategic financial goals.

Investment Management

This department focuses on conducting research and developing innovative projects to advance organizational objectives.

Research and Development

This department oversees the strategic direction and overall management of the organization.

Executive Leadership

This department is responsible for managing and supporting the organization's information technology systems and consulting on project implementations.

HERVolution Therapeutics

Org chart

Teams

Investment Management

Research and Development

Executive Leadership

IT Services

Offices

HERVolution Therapeutics

Org chart

Teams

Investment Management

Research and Development

Executive Leadership

IT Services

Offices

Related companies